Merck Pre-Tax Profit Margin 2010-2024 | MRK

Current and historical pre-tax profit margin for Merck (MRK) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Merck pre-tax profit margin for the three months ending March 31, 2024 was .
Merck Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2024-03-31 $61.40B $3.91B 6.37%
2023-12-31 $60.12B $1.89B 3.14%
2023-09-30 $59.31B $7.45B 12.56%
2023-06-30 $58.31B $5.41B 9.28%
2023-03-31 $57.87B $15.23B 26.32%
2022-12-31 $59.28B $16.44B 27.74%
2022-09-30 $58.97B $16.84B 28.55%
2022-06-30 $57.17B $18.52B 32.40%
2022-03-31 $53.98B $15.75B 29.18%
2021-12-31 $48.70B $13.88B 28.50%
2021-09-30 $44.36B $6.55B 14.76%
2021-06-30 $42.14B $3.99B 9.46%
2021-03-31 $40.09B $5.01B 12.50%
2020-12-31 $41.52B $5.86B 14.12%
2020-09-30 $36.49B $7.78B 21.33%
2020-06-30 $37.96B $7.42B 19.56%
2020-03-31 $40.36B $7.94B 19.68%
2019-12-31 $39.12B $7.17B 18.33%
2019-09-30 $45.97B $11.28B 24.53%
2019-06-30 $44.37B $11.60B 26.14%
2019-03-31 $43.07B $10.42B 24.20%
2018-12-31 $42.29B $8.70B 20.57%
2018-09-30 $41.73B $7.98B 19.11%
2018-06-30 $41.26B $5.51B 13.35%
2018-03-31 $40.73B $5.86B 14.40%
2017-12-31 $40.12B $6.52B 16.25%
2017-09-30 $39.80B $3.29B 8.26%
2017-06-30 $40.02B $5.97B 14.93%
2017-03-31 $39.93B $5.04B 12.62%
2016-12-31 $39.81B $4.66B 11.70%
2016-09-30 $39.91B $6.83B 17.12%
2016-06-30 $39.44B $6.34B 16.08%
2016-03-31 $39.39B $5.64B 14.33%
2015-12-31 $39.50B $5.40B 13.67%
2015-09-30 $39.77B $16.40B 41.23%
2015-06-30 $40.25B $15.49B 38.48%
2015-03-31 $41.40B $16.57B 40.03%
2014-12-31 $42.24B $17.28B 40.92%
2014-09-30 $43.08B $6.70B 15.55%
2014-06-30 $43.55B $6.73B 15.46%
2014-03-31 $43.63B $6.09B 13.95%
2013-12-31 $44.03B $5.55B 12.59%
2013-09-30 $44.45B $5.65B 12.72%
2013-06-30 $44.91B $6.35B 14.13%
2013-03-31 $46.21B $7.78B 16.84%
2012-12-31 $47.27B $8.74B 18.49%
2012-09-30 $47.82B $8.99B 18.79%
2012-06-30 $48.36B $9.12B 18.86%
2012-03-31 $48.20B $8.11B 16.83%
2011-12-31 $48.05B $7.33B 15.26%
2011-09-30 $47.85B $5.05B 10.56%
2011-06-30 $46.95B $3.20B 6.81%
2011-03-31 $46.15B $2.77B 5.99%
2010-12-31 $45.99B $1.65B 3.59%
2010-09-30 $43.99B $8.82B 20.05%
2010-06-30 $38.91B $13.40B 34.43%
2010-03-31 $33.47B $14.12B 42.20%
2009-12-31 $27.43B $15.29B 55.75%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $318.855B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $860.678B 124.39
Novo Nordisk (NVO) Denmark $607.702B 46.70
Johnson & Johnson (JNJ) United States $376.838B 14.94
AbbVie (ABBV) United States $309.504B 15.99
AstraZeneca (AZN) United Kingdom $247.297B 21.50
Novartis AG (NVS) Switzerland $228.519B 16.20
Pfizer (PFE) United States $170.168B 21.15
Sanofi (SNY) $127.168B 11.98
Innoviva (INVA) United States $1.090B 7.66